key: cord-0688308-2e9zcq5v
authors: van Ogtrop, M. L.; van de Laar, T. J. W.; Eggink, D.; Vanhommerig, J. W.; van der Reijden, W. A.
title: Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants
date: 2021-11-24
journal: Microbiology spectrum
DOI: 10.1128/spectrum.00884-21
sha: 58184854540a4348bbaee8beafb6d33928a714cf
doc_id: 688308
cord_uid: 2e9zcq5v

This study evaluates the performance of the PanBio COVID-19 antigen (Ag) test as part of a hospital infection control policy. Hospital staff was encouraged to get tested for COVID-19 when presenting with SARS-CoV-2-related symptoms. In a period of approximately 5 months, a steady decline in the performance of the Ag test was noted, epidemiologically coinciding with the rise of the SARS-CoV-2 B.1.1.7 (alpha) variant of concern (VOC) in the Netherlands. This led to the hypothesis that the diagnostic performance of the PanBio COVID-19 Ag test was influenced by the infecting viral variant. The results show a significantly lower sensitivity of the PanBio COVID-19 Ag test in persons infected with the B.1.1.7 (alpha) variant of SARS-CoV-2 in comparison with that in persons infected with non-B.1.1.7 variants, also after adjustment for viral load. IMPORTANCE Antigen tests for COVID-19 are widely used for rapid identification of COVID-19 cases, for example, for access to schools, festivals, and travel. There are several FDA- and CE-cleared tests on the market. Their performance has been evaluated mainly on the basis of infections by the classical variant of the causing virus, SARS-CoV-2. This paper provides evidence that the performance of one of the most widely used antigen tests detects significantly fewer cases of COVID-19 by the alpha variant than by the classical variants of SARS-CoV-2. This means that the role of antigen tests needs to be reevaluated in regions where other variants of SARS-CoV-2 predominate.

(7.3%) tested SARS-CoV-2 RNA positive using transcription-mediated amplification (TMA). All 47 SARS-CoV-2 Ag-positive HCWs also tested positive for SARS-CoV-2 RNA using TMA, and the remaining 28 SARS-CoV-2 RNA-positive samples tested SARS-CoV-2 Ag negative. Real-time PCR (RT-PCR) confirmed the presence of SARS-CoV-2 RNA in all 75 TMA-positive samples. Some HCWs were tested more than once, but none of them had more than one SARS-CoV-2 RNA-positive sample. We did not include sequential samples of one viremic episode, and we did not observe episodes of reinfections. Using NAAT as the gold standard, there were no false-positive Ag tests, indicating 100% specificity of the SARS-CoV-2 Ag test. Overall sensitivity of the COVID-19 Ag test was 62.7% (47/75 SARS-CoV-2 RNA-positive HCWs were detected using Ag testing). However, the sensitivity of Ag testing decreased over time from 90.1% in November 2020, to 82.4% in December 2020, to rates varying between 66.7% and 37.5% in January to April 2021. We speculated that aside from viral load (as indicated by the manufacturer), the circulating viral variant might also influence the sensitivity of the SARS-CoV-2 Ag test. Figure 1 

Our study showed a decreasing sensitivity of the PanBio COVID-19 Ag test over time, which was traced back to the rapid emergence of the SARS-CoV-2 B.1.1.7 (alpha) variant. After correction for viral load, infections with the SARS-CoV-2 B.1.1.7 (alpha) variant were 7.4 times more likely to result in a SARS-CoV-2 Ag-negative test result compared to SARS-CoV-2 infections with non-alpha lineages. This finding might have serious implications for the use of SARS-CoV-2 Ag tests, since Ag testing has been advocated as a potential aid in the solution of reopening schools, mass events, and international travel (2). The ECDC states that "the use of rapid Ag tests is appropriate in high prevalence settings when a positive result is likely to indicate true infection, as well as in low prevalence settings to rapidly identify highly infectious cases. Rapid Ag tests can help reduce further transmission through early detection of highly infectious cases, enabling a rapid start of contact tracing" (www.ecdc.europa.eu/sites/default/files/documents/Options-use-of-rapid-antigen -tests-for-COVID-19.pdf). The PanBio COVID-19 Ag test has been studied extensively, generally with favorable results. A recent Cochrane review reported an average clinical sensitivity of 75.1% in symptomatic persons (1) . Previous estimates of the sensitivity of the PanBio COVID-19 Ag test in the Netherlands varied between 53 and 93% (https://lci.rivm.nl/sites/default/files/2021-02/Status%20validatie%20SARS-CoV-2% 20antigeensneltesten%208%20februari%202021.pdf), depending on the population studied. Our population consisted entirely of adult HCWs with mild to moderate symptoms, who were tested in an early phase of their infection. Furthermore, the samples were taken by experienced and trained personnel of the emergency department and were processed and analyzed within one hour by experienced and trained laboratory personnel. All these factors contribute to a fairly consistent database.

A possible explanation for the lower sensitivity of the Ag test in the case of the B.1.1.7 (alpha) variant could be that mutations characterizing this variant result in a virus particle that binds less avidly to the antibodies present in the PanBio COVID-19 Ag test. As this assay targets the nucleocapsid protein, it is more likely that B.1.1.7-associated nucleocapsid mutations are responsible for the lower observed sensitivity for B.1.1.7 variants and not the B.1.1.7 characteristic N501Y mutation in the S glycoprotein. The S235F nucleocapsid mutation could be a potential candidate. Epitopes rendered from the S235F mutation proved incapable of binding antibodies generated against the original virus, which could explain false-negative test results (3) . On the other hand, structure-function analyses show that the S235F occurs outside the RNA and protein binding domain, suggesting no effect on Ag test results (4) . Further research is needed to elucidate the mechanism or mutations responsible for the decreased sensitivity of the B.1.1.7 variant for the PanBio COVID-19 Ag test.

The B.1.1.7 (alpha) variant has a higher infectivity because of an increased affinity Ag test stipulates testing within the 7-day window of infection. Although HCWs were strongly requested to test immediately with the onset of even the mildest COVID-19related symptoms, it cannot be excluded that, e.g., due to so-called testing fatigue, over time HCWs postponed SARS-CoV-2 testing until presentation of more severe symptoms. Lastly, the VirSNiP assay used for B.1.1.7 typing between November 2020 and January 2021 cannot distinguish between B.1.1.7 (alpha) and other N501Y-bearing strains, including B.1.351 (beta) and P.1 (gamma). In total, 7/30 B.1.1.7 (alpha) variants in this study were characterized as B.1.1.7 (alpha) based solely on the presence of the N501Y mutation. Although we cannot exclude incidental misclassification, the background prevalence of non-B.1.1.7 strains bearing the N501Y mutation in the Netherlands during that time was very low, making it unlikely to influence our conclusions. Only 27/514 (4.7%) of N501Y-bearing strains in the national SARS-CoV-2 surveillance database were non-B.1.1.7, and within our region the number was even lower (2.8%). The national SARS-CoV-2 surveillance database consists of a random sample of SARS-CoV-2 patients in the Netherlands (https://www.rivm.nl/coronavirus-covid-19/ onderzoek/kiemsurveillance).

All in all, our data suggest that SARS-CoV-2 variants might develop into distinguishable viruses, each with their own dynamics regarding epidemiology, control measures, vaccination efficacy, and diagnostic characteristics. In this regard, it is worthwhile to consider the diagnostic value of Ag testing as a variable that could be dependent on the variant of the SARS-CoV-2 as well, but larger studies and studies with different Ag tests are needed to corroborate our preliminary results.

Subjects and specimen collection. BovenIJ hospital is a small community hospital in Amsterdam, the Netherlands. As part of its COVID-19 infection prevention program, health care workers (HCWs) with COVID-19-related symptoms were strongly encouraged to test for SARS-CoV-2. The COVID-19 infection control policy of the hospital was consistent throughout the entire study period. SARS-CoV-2 laboratory testing always consisted of both SARS-CoV-2 Ag testing and nucleic acid amplification testing (NAAT). This study includes all SARS-CoV-2 test results, both Ag and NAAT, obtained from HCWs during the period of 11 November 2020 to 20 April 2021. All specimens were collected by trained nurses using flocked swabs, following appropriate safety precautions. In total, 3 swabs were collected, one nasopharyngeal swab for Ag testing and one nasopharyngeal plus one oropharyngeal swab for NAAT. The two swabs for NAAT were combined into one single tube containing 3 mL universal transport medium (UTM, Becton Dickinson, Sparks, MD, USA). Specimens for Ag testing were discarded directly after testing, and specimens for NAAT were stored at 280°C.

SARS-CoV-2 antigen testing. The PanBio COVID-19 Ag test (Abbott, Lake Country, IL, USA) is a membrane-based immunochromatography assay for the detection of SARS-CoV-2 nucleocapsid protein from nasopharyngeal swabs. The test was performed according to the manufacturer's instructions (reading time 15 minutes) by trained technicians of the clinical laboratory of BovenIJ hospital within one hour after specimen collection.

SARS-CoV-2 nucleic acid amplification testing. The Aptima SARS-CoV-2 assay for the Panther system (Hologic Inc., San Diego, CA, USA) is a transcription-mediated amplification (TMA) dual target assay that amplifies and detects two conserved regions of the SARS-CoV-2 ORF1ab gene. Amplicon detection uses chemiluminescent probes with distinct kinetic profiles: light emission with slow kinetics (glower) for both ORF1ab amplicons and light emission with rapid kinetics for the internal control (flasher). Amplification of at least one of the ORF1ab fragments generates a glower-type light signal quantified in relative light units (RLU). RLU signal strength cannot be used as a semiquantitative measure for SARS-CoV-2 RNA due to rapid saturation. According to the manufacturer, the analytical sensitivity of the Aptima SARS-CoV-2 assay is 83 copies/mL. The assay was performed by trained technicians of the clinical microbiology laboratory of OLVG Lab BV within 24 hours after specimen collection.

All SARS-CoV-2 RNA-positive samples were retested using the Realstar SARS-CoV2 RT-PCR (Altona Diagnostics GmbH, Hamburg, Germany) to obtain a semiquantitative measure as a proxy for viral load (expressed as Cp value). The Realstar SARS-CoV-2 RT-PCR is a dual target assay that amplifies and detects fragments of the S-gene (SARS-CoV-2 specific, Cy5 channel) and the E-gene (b-coronavirus lineage B specific, FAM channel). Nucleic extraction, amplification, and detection were performed with the MagNA Pure 96 system and Lightcycler 480 instrument II (Roche Diagnostics, Rotkreuz, Switzerland). According to the manufacturer, the analytical sensitivity of the Realstar SARS-CoV-2 RT-PCR is 140 copies/mL. The Realstar SARS-CoV-2 assay was performed by trained technicians of the clinical microbiology laboratory of OLVG Lab BV using stored NAAT specimens.

SARS-CoV-2 B.1.1.7 typing. All confirmed SARS-CoV-2 RNA-positive samples were typed to distinguish between the SARS-CoV-2 B.1.1.7 (alpha) variant versus classical SARS-CoV-2 variants not bearing the N501Y mutation. Samples obtained during the study period November 2020 to January 2021 were characterized using the melting curve-based SARS Spike 501 VirSNiP assay (TIB MOLBIOL GmbH, Berlin, Germany). All samples bearing the N501Y mutation were classified as suspected B.1.1.7 variants. For SARS-CoV-2 RNA-positive samples obtained after January 2021, the full SARS-CoV-2 genome sequences were obtained using Nanopore sequencing based on the ARTIC v3 amplicon sequencing protocol (https://artic.network). Full genome sequences were deposited at the GISAID repository (7) .

Ethical statement. Ethical approval for this study was not required, because the study was an observational study performed on samples which were collected as part of standard hospital infection prevention policy. All subjects had given consent for inclusion in this report by an opt out e-mail procedure.

Statistics. As statistical software, SPSS was used (IBM Corp. Released 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp.). Results were analyzed by the Fisher's exact test and Student's t test, with a P value of ,0.05 considered statistically significant. Multivariable logistic regression analysis was used to obtain odds ratios (OR) adjusted for Cp value.

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, XLSX file, 0.01 MB.

Van den Bruel A, Cochrane COVID-19 Diagnostic Test Accuracy Group. 2021. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Real-life validation of the Panbio COVID19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection

Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern

Structure-function analyses of new SARS-CoV-2 variants B.1.1.7, B.1.351 and B.1.1.28.1: clinical, diagnostic, therapeutic and public health implications

Functional binding dynamics relevant to the evolution of zoonotic spillovers in endemic and emergent Betacoronavirus strains

Estimating infectiousness throughout SARS-CoV-2 infection course

Data, disease and diplomacy: GISAID's innovative contribution to global health

All authors have substantially contributed to the design of the study, the draft of the paper, and the approval of the final version. M.L.O supervised the microbiological part of the study and was responsible for the infection control policy, T.J.W.L. and W.A.R. supervised the molecular-biological part of the study, J.V. was responsible for statistical analysis, and D.E. was responsible for NGS and provided national and local data on circulating SARS-CoV-2 variants. No external funding was received.We declare no conflicts of interest.